JLB & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.39M | Sell |
37,301
-1,048
| -3% | -$225K | 1.25% | 30 |
|
|
2026
Q1 | $8.34M | Sell |
38,349
-2,304
| -6% | -$511K | 1.2% | 33 |
|
|
2025
Q4 | $9.29M | Sell |
40,653
-1,260
| -3% | -$287K | 1.25% | 32 |
|
|
2025
Q3 | $9.7M | Sell |
41,913
-440
| -1% | -$89.6K | 1.28% | 32 |
|
|
2025
Q2 | $7.86M | Sell |
42,353
-1,454
| -3% | -$270K | 1.1% | 34 |
|
|
2025
Q1 | $9.18M | Sell |
43,807
-461
| -1% | -$89.6K | 1.28% | 32 |
|
|
2024
Q4 | $7.87M | Sell |
44,268
-1,020
| -2% | -$188K | 1.07% | 34 |
|
|
2024
Q3 | $8.94M | Sell |
45,288
-390
| -0.9% | -$72.8K | 1.15% | 33 |
|
|
2024
Q2 | $7.83M | Sell |
45,678
-185
| -0.4% | -$30.6K | 1.06% | 35 |
|
|
2024
Q1 | $8.35M | Sell |
45,863
-1,110
| -2% | -$191K | 1.11% | 36 |
|
|
2023
Q4 | $7.28M | Sell |
46,973
-309
| -0.7% | -$45K | 1.05% | 35 |
|
|
2023
Q3 | $7.05M | Sell |
47,282
-4,300
| -8% | -$631K | 1.11% | 35 |
|
|
2023
Q2 | $6.95M | Hold |
51,582
| – | – | 0.99% | 36 |
|
|
2023
Q1 | $8.22M | Sell |
51,582
-30
| -0.1% | -$4.59K | 1.24% | 34 |
|
|
2022
Q4 | $8.34M | Sell |
51,612
-75
| -0.1% | -$11.5K | 1.33% | 32 |
|
|
2022
Q3 | $6.94M | Sell |
51,687
-30
| -0.1% | -$4.3K | 1.23% | 33 |
|
|
2022
Q2 | $7.92M | Sell |
51,717
-931
| -2% | -$142K | 1.35% | 33 |
|
|
2022
Q1 | $8.53M | Buy |
52,648
+245
| +0.5% | +$35.6K | 1.28% | 33 |
|
|
2021
Q4 | $7.09M | Hold |
52,403
| – | – | 1.01% | 37 |
|
|
2021
Q3 | $5.65M | Sell |
52,403
-1,200
| -2% | -$137K | 0.9% | 38 |
|
|
2021
Q2 | $6.04M | Sell |
53,603
-650
| -1% | -$73.2K | 0.94% | 40 |
|
|
2021
Q1 | $5.87M | Sell |
54,253
-2,505
| -4% | -$268K | 0.97% | 40 |
|
|
2020
Q4 | $6.08M | Sell |
56,758
-140
| -0.2% | -$13.5K | 1.01% | 36 |
|
|
2020
Q3 | $4.98M | Sell |
56,898
-250
| -0.4% | -$23.5K | 0.92% | 38 |
|
|
2020
Q2 | $5.61M | Buy |
57,148
+330
| +0.6% | +$29.1K | 1.12% | 35 |
|
|
2020
Q1 | $4.33M | Sell |
56,818
-4,615
| -8% | -$393K | 1.03% | 36 |
|
|
2019
Q4 | $5.44M | Sell |
61,433
-325
| -0.5% | -$27K | 1% | 37 |
|
|
2019
Q3 | $4.68M | Sell |
61,758
-1,057
| -2% | -$72.5K | 0.93% | 37 |
|
|
2019
Q2 | $4.57M | Buy |
62,815
+22
| +0% | +$1.73K | 0.92% | 38 |
|
|
2019
Q1 | $5.06M | Hold |
62,793
| – | – | 1.07% | 37 |
|
|
2018
Q4 | $5.79M | Buy |
62,793
+187
| +0.3% | +$16.4K | 1.41% | 33 |
|
|
2018
Q3 | $5.92M | Sell |
62,606
-5,056
| -7% | -$479K | 1.27% | 36 |
|
|
2018
Q2 | $6.27M | Sell |
67,662
-290
| -0.4% | -$28.3K | 1.33% | 36 |
|
|
2018
Q1 | $6.43M | Sell |
67,952
-2,325
| -3% | -$255K | 1.38% | 34 |
|
|
2017
Q4 | $6.8M | Buy |
70,277
+4,643
| +7% | +$438K | 1.48% | 35 |
|
|
2017
Q3 | $5.83M | Buy |
65,634
+5,285
| +9% | +$402K | 1.42% | 34 |
|
|
2017
Q2 | $4.38M | Buy |
+60,349
| New | +$4.06M | 1.11% | 38 |
|
|
2016
Q4 | $4.15M | Sell |
66,225
-665
| -1% | -$40.6K | 1.12% | 38 |
|
|
2016
Q3 | $4.22M | Sell |
66,890
-1,175
| -2% | -$76.1K | 1.16% | 38 |
|
|
2016
Q2 | $4.21M | Buy |
68,065
+1,880
| +3% | +$115K | 1.19% | 38 |
|
|
2016
Q1 | $4.31M | Sell |
66,185
-2,483
| -4% | -$138K | 1.1% | 37 |
|
|
2015
Q4 | $4.07M | Sell |
68,668
-142
| -0.2% | -$8.18K | 1.26% | 36 |
|
|
2015
Q3 | $3.74M | Sell |
68,810
-300
| -0.4% | -$19.5K | 1.21% | 36 |
|
|
2015
Q2 | $4.64M | Buy |
69,110
+155
| +0.2% | +$10.1K | 1.44% | 32 |
|
|
2015
Q1 | $4.04M | Sell |
68,955
-425
| -0.6% | -$25.7K | 1.26% | 35 |
|
|
2014
Q4 | $4.54M | Sell |
69,380
-125
| -0.2% | -$7.88K | 1.51% | 31 |
|
|
2014
Q3 | $4.01M | Sell |
69,505
-623
| -0.9% | -$34.6K | 1.44% | 30 |
|
|
2014
Q2 | $3.96M | Hold |
70,128
| – | – | 1.44% | 32 |
|
|
2014
Q1 | $3.6M | Hold |
70,128
| – | – | 1.34% | 33 |
|
|
2013
Q4 | $3.7M | Buy |
70,128
+30
| +0% | +$1.47K | 1.41% | 33 |
|
|
2013
Q3 | $3.13M | Buy |
70,098
+770
| +1% | +$34.1K | 1.32% | 35 |
|
|
2013
Q2 | $2.87M | Buy |
+69,328
| New | +$3.03M | 1.31% | 35 |
|
Other funds holding ABBV
JLB & Associates's ABBV Position: Q2 2026 in Review
JLB & Associates reduced its AbbVie (ABBV) stake by 2.7% in Q2 2026, selling an estimated $225K and leaving 37,301 shares worth $9.39M. The position accounts for 1.25% of the portfolio, ranked #30.
JLB & Associates first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.7M in Q3 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- JLB & Associates held 37,301 shares of AbbVie worth $9.39M as of Q2 2026.
- JLB & Associates sold 1,048 AbbVie shares in Q2 2026, an estimated $225K.
- AbbVie made up 1.25% of JLB & Associates's portfolio in Q2 2026, its #30 holding.
- JLB & Associates first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- JLB & Associates's AbbVie position peaked at $9.7M in Q3 2025.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on JLB & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.